Genezen
Genezen is a U.S.-based CDMO providing lentiviral, retroviral, and AAV viral vector manufacturing, cell therapy services, and analytical testing for gene and cell therapy developers across two cGMP facilities in Indiana and Massachusetts.
- Company typePrivate
- Founded2014
- HeadquartersIndianapolis, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Genezen does
Genezen is a privately held contract development and manufacturing organization (CDMO) specializing in viral vector production for gene and cell therapy developers. Founded in 2014 in Indianapolis by Bill Vincent, the company operates from two U.S. facilities: a 60,000 ft² cGMP multi-vector production site in Fishers, Indiana (originally completed in 2022) and an 86,000 ft² commercial gene therapy manufacturing facility in Lexington, Massachusetts acquired from uniQure in 2024. Services span end-to-end lentiviral, retroviral, and adeno-associated virus (AAV) vector manufacturing, plasmid design, cell therapy manufacturing, analytical development and testing, and a discovery-stage offering branded Propel: Discovery.
The company's technical platform rests on a licensed exclusive agreement with CSL for the Cytegrity™ stable lentivirus production system (with demonstrated functional titers up to 1e7 TU/mL), proprietary suspension HEK293T cell lines and synthetic DNA workflows, and fixed-bed bioreactor systems enabling scalable production with reduced batch-to-batch variability. Genezen supports FDA and EMA-compliant GMP production and has demonstrated regulatory readiness through late-stage and pivotal clinical supply partnerships.
Genezen generates revenue through fee-for-service CDMO contracts with biotech and pharmaceutical companies developing gene and cell therapies. The customer base spans gene therapy developers, cell therapy companies, rare disease foundations, and academic research institutions, including named engagements with Atsena Therapeutics (commercial manufacturing partnership targeting 2028 BLA), Seattle Children's Research Institute, Optieum Biotechnologies, Humane Genomics, The Charlotte & Gwenyth Gray Foundation, and Elly's Team. Go-to-market is executed through direct enterprise sales, industry conferences (ASGCT, BIO International, MassBio), and academic partnerships; pricing is quote-based and not publicly disclosed. The company is majority-backed by Ampersand Capital Partners following an $18.5 million growth equity investment in November 2023.
Genezen firmographics
Firmographics- Name
- Genezen
- Legal name
- Genezen Laboratories, Inc.
- Website
- https://genezen.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Genezen is a U.S.-based CDMO providing lentiviral, retroviral, and AAV viral vector manufacturing, cell therapy services, and analytical testing for gene and cell therapy developers across two cGMP facilities in Indiana and Massachusetts.
- Ownership category
- akta.pro rank
Genezen industry classification
Industry- Product category
- Viral Vector and Cell Therapy Contract Manufacturing (CDMO)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where Genezen is headquartered
LocationHeadquarters
- HQ city
- Indianapolis
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Genezen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- CDMO Manufacturing Services: Fee-for-service contract development and manufacturing organization providing viral vector manufacturing, process development, analytical testing, and cell therapy services to biotech and pharma companies on a project basis.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Genezen product offering
Product offeringCore offering
Genezen is a contract development and manufacturing organization (CDMO) providing end-to-end viral vector and cell therapy manufacturing services for gene therapy developers. Its offering spans lentiviral, retroviral, adeno-associated virus (AAV), plasmid, and cell therapy manufacturing supported by analytical development and testing services, delivered across two cGMP-compliant facilities in Fishers, Indiana and Lexington, Massachusetts.
Product overview
Genezen is a contract development and manufacturing organization (CDMO) providing a comprehensive suite of viral vector and cell therapy manufacturing services. The core offering comprises Lentiviral Vector CDMO Services, Retroviral Vector CDMO Services, Adeno-Associated Viral Vector CDMO Services, Cell Therapy CDMO Services, and Plasmids Manufacturing, supported by Analytical Development and Testing Services. The company also offers Propel: Discovery for early-stage programs. Genezen's manufacturing is powered by proprietary technology platforms including the Cytegrity Stable Lentivirus Production System and Fixed-Bed Bioreactor Manufacturing Platform. Services span from pre-clinical research through commercial-scale manufacturing across two facilities: a 60,000 ft2 development and manufacturing facility in Fishers, Indiana, and an 86,000 ft2 commercial-scale facility in Lexington, Massachusetts.
Differentiator
Problem solved
Functional benefit
Products and services
- Lentiviral Vector CDMO Services End-to-end lentiviral vector manufacturing services from plasmid design and cell line development through GMP production, supporting both adherent and suspension processes with single-use technology. Targeted at gene therapy developers requiring clinical and commercial-grade lentiviral vectors.
- Retroviral Vector CDMO Services Retroviral vector manufacturing services utilizing state-of-the-art facilities designed for aseptic manufacture, delivering larger batches with consistency and reliability. Designed for gene and cell therapy developers needing retroviral vector production.
- Cell Therapy CDMO Services Cell therapy manufacturing services leveraging world-class partnerships to streamline production and advance cell therapies from trial through commercialization. Supports CAR-T and other cell therapy developers requiring integrated viral vector and cell therapy manufacturing.
- Plasmids Manufacturing Plasmid design and manufacturing services, utilizing preferred partners' proven platforms or working with client-provided plasmids to meet unique requirements. Supports gene therapy developers across the manufacturing lifecycle.
- Adeno-Associated Viral Vector CDMO Services AAV vector manufacturing services leveraging over a decade of experience with diverse platforms, processes, and analytics to advance programs from molecule to medicine. Targeted at gene therapy developers across preclinical, clinical, and commercial stages.
- Propel: Discovery Discovery-stage support services designed to accelerate early development gene and cell therapy programs through Genezen's expertise and facilities. Targeted at developers in the earliest preclinical phases.
- Analytical Development and Testing Services Comprehensive testing services including potency assays (biological titers, vector genome titers, TCID50), identity testing (VCN, insert stability, genome integrity by NGS), stability testing, purity testing, residual testing, and safety testing (RCL/RCR assays, sterility, endotoxin, mycoplasma).
Quantifiable outcome
- Demonstrated functional titers of up to 1e7 TU/mL using Cytegrity™ system
- +2 more outcomes
Companies that use Genezen
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
Genezen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Genezen partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered secondary, core and minor.
- SGSsecondaryExpanded partnership to strengthen support for foundation-funded gene therapy programs, providing comprehensive testing and quality services for rare disease therapies.
- The Charlotte & Gwenyth Gray Foundation to Cure Batten DiseasesecondaryManufacturing partnership to advance CLN6 gene therapy into Phase 1/2 clinical trial for Batten disease. Genezen supported rapid progression from proof of concept to GMP clinical supply using its viral vector platform and regulatory expertise, including direct FDA engagement.
- Atsena TherapeuticscoreStrategic commercial manufacturing partnership for clinical development and commercial manufacturing of Atsena's AAV gene therapy pipeline, including ATSN-201 for X-linked retinoschisis targeting BLA filing in early 2028. Genezen leverages its viral vector manufacturing expertise to provide a streamlined and cost-efficient path to commercial manufacturing.
- Atsena TherapeuticscoreManufacturing partnership supporting Atsena's pivotal LIGHTHOUSE study for XLRS treatment and advancing programs toward regulatory approval and commercial launch.
- Humane GenomicssecondaryPartnership to develop and manufacture HGI627, an oncolytic viral therapy targeting pediatric liver cancer. Collaboration involves process transfer and cGMP manufacturing using Humane Genomics' proprietary RNA virus platform.
- Optieum BiotechnologiessecondaryPartnership to support cGMP manufacturing of groundbreaking CAR-T therapy for glioblastoma, leveraging Genezen's viral vector and cell therapy manufacturing capabilities.
- Elly's TeamsecondaryPartnership for AAV9 gene replacement therapy targeting NEDAMSS (Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures). Genezen provided CMC expertise for development of analytical/ancillary studies to support IND submission, and Dr. Susan D'Costa joined the foundation's board.
- Seattle Children's Research InstitutesecondaryStrategic manufacturing partnership for X-linked agammaglobulinemia (XLA) cell therapy program. Licensing of proven stable producer system for lentiviral vector production provides clients access to cutting-edge technology for stable and scalable high-titer clinical lentivirus production.
- CSLcoreLicensing agreement for Cytegrity™ proprietary stable lentivirus production system from CSL. This next-generation technology offers remarkable efficiency, streamlined and cost-effective solution, seamless scalability, and reduced batch-to-batch variability with demonstrated functional titers up to 1e7 TU/mL.
- Indiana UniversitysecondaryResearch institution partnership providing access to the Indiana University Gene Therapy Testing Laboratory for clinical trial subject testing and release testing services, including RCL/RCR testing, PCR testing, insertion site analysis, and p24 ELISA.
- Cincinnati Children's Hospital Medical CentersecondaryResearch partnership with Cincinnati Children's Hospital Medical Center Translational Core Laboratory providing access to expertise in transducing hematopoietic progenitors, stem cells, T lymphocytes, and other immune cells for cell therapy manufacturing services.
- Vanguard Clinical, Inc.minorCollaboration with Vanguard Clinical for development support on CLN6 Batten disease program, with CEO Tiffany Sepp serving as Development Team Leader for the Gray Foundation.
Scale indicators4 records
Recent moves9 records
Expansion highlights6 records
Genezen competitors and assessment
Company assessmentDirect peers
- Andelyn Biosciences: Columbus, OH-based viral vector CDMO offering lentiviral, AAV, and other viral vector manufacturing for gene therapy developers. Closely comparable to Genezen in multi-modality vector manufacturing, scale (similar facility footprint), and customer base (early- to mid-stage gene therapy developers).
- Forge Biologics: Columbus, OH-based CDMO focused on AAV viral vector manufacturing and gene therapy development services. Direct competitor in the AAV CDMO space with overlapping customer segments (gene therapy biotechs from preclinical through commercial) and similar technology platform approach.
- Viralgen (AskBio/Bayer): Spanish AAV CDMO owned by AskBio (acquired by Bayer), one of the largest dedicated viral vector manufacturers globally. Comparable to Genezen in AAV manufacturing focus, though at significantly larger scale and with European footprint advantage for global gene therapy sponsors.
- Yposkesi (SK pharmteco): France-based lentiviral and AAV CDMO (formerly Yposkesi), now part of SK pharmteco. Highly comparable to Genezen in lentiviral vector manufacturing focus, multi-vector platform, and biotech client base; provides Genezen's main European-headquartered competition for viral vector programs.
Broad incumbents
- Catalent (Novo Holdings): Large-scale global CDMO with viral vector manufacturing services for cell and gene therapies. Comparable as an incumbent competitor offering broader CDMO services (biologics fill-finish, oral dose forms) plus gene therapy vector production, competing with Genezen for larger gene therapy manufacturing RFPs.
- Thermo Fisher Scientific (Patheon/Brammer Bio): Global life sciences services platform that acquired Brammer Bio (viral vector CDMO). Competes with Genezen across the viral vector CDMO space with significantly greater scale, integrated services, and balance sheet, particularly for late-stage and commercial gene therapy programs.
- Lonza: Swiss global CDMO leader offering viral vector and cell therapy manufacturing services. Comparable to Genezen in viral vector and cell therapy manufacturing, but operating at substantially larger scale with broader biologics portfolio and global geographic footprint.
- Resilience: Biomanufacturing technology company offering viral vector, cell therapy, and biologics manufacturing services. Compares to Genezen in viral vector CDMO services, with broader biomanufacturing portfolio and significant capital backing from public and private sources.
Emerging players
- AavantiBio: AAV-focused gene therapy CDMO spun out from the University of Florida. Compares to Genezen in AAV manufacturing focus and gene therapy developer client base, though operating at earlier commercial scale and narrower single-modality platform.
- Avectas (formerly Solentim): Cell engineering technology company supporting cell therapy developers including GMP manufacturing support. Adjacent peer to Genezen's cell therapy CDMO offering, with overlapping customer base in CAR-T and other cell therapy developers requiring lentiviral vector supply.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Genezen social profiles
Digital presenceGenezen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genezen leadership team
Management profileNumber of profiles
Profiles5 records
Genezen funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genezen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genezen
What does Genezen do?
Genezen is a contract development and manufacturing organization (CDMO) providing end-to-end viral vector and cell therapy manufacturing services for gene therapy developers. Its offering spans lentiviral, retroviral, adeno-associated virus (AAV), plasmid, and cell therapy manufacturing supported by analytical development and testing services, delivered across two cGMP-compliant facilities in Fishers, Indiana and Lexington, Massachusetts.
Is Genezen a public or private company?
Genezen is a private company. It is classified as private equity controlled and is currently operating.
When was Genezen founded?
Genezen was founded in 2014. It employs 251 to 500 people.
Where is Genezen based?
Genezen is headquartered in Indianapolis, United States, in the North America region.
How does Genezen make money?
One revenue line is on record: CDMO Manufacturing Services.
Who are Genezen's main competitors?
Direct peers on record are Andelyn Biosciences, Forge Biologics, Viralgen (AskBio/Bayer) and Yposkesi (SK pharmteco). Broad incumbents are Catalent (Novo Holdings), Thermo Fisher Scientific (Patheon/Brammer Bio), Lonza and Resilience. Emerging players are AavantiBio and Avectas (formerly Solentim).
Does Genezen have an API?
No public API is recorded for Genezen.
What industry is Genezen in?
Genezen's product category is Viral Vector and Cell Therapy Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 541714 and its SIC code is 8731.